Associations - Truqap (capivasertib)

PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
AKT1 mutation + HR positive	HER2 Negative Breast Cancer	AKT1 mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PTEN mutation + HR positive	HER2 Negative Breast Cancer	PTEN mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PTEN deletion + ER positive	HER2 Negative Breast Cancer	PTEN deletion + ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
AKT1 mutation + ER positive	HER2 Negative Breast Cancer	AKT1 mutation + ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
AKT1 mutation + ER positive	Breast Cancer	AKT1 mutation + ER positive	Breast Cancer	capivasertib Sensitive: C1 - Off-label capivasertib Sensitive : C1	capivasertib Sensitive: C1 - Off-label capivasertib Sensitive : C1
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2
PIK3CA mutation	Gastric Cancer	PIK3CA mutation	Gastric Cancer	capivasertib Sensitive: C2 – Inclusion Criteria capivasertib Sensitive : C2	capivasertib Sensitive: C2 – Inclusion Criteria capivasertib Sensitive : C2
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2
PTEN mutation	Estrogen Receptor Positive Breast Cancer	PTEN mutation	Estrogen Receptor Positive Breast Cancer	capivasertib Sensitive: C2 – Inclusion Criteria capivasertib Sensitive : C2	capivasertib Sensitive: C2 – Inclusion Criteria capivasertib Sensitive : C2
AKT1 E17K	Salivary Gland Cancer	AKT1 E17K	Salivary Gland Cancer	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
AKT1 E17K + HR positive	HER2 Negative Breast Cancer	AKT1 E17K + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
AKT1 E17K	Uterine Corpus Leiomyosarcoma	AKT1 E17K	Uterine Corpus Leiomyosarcoma	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
AKT1 mutation + ER negative	Breast Cancer	AKT1 mutation + ER negative	Breast Cancer	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
TP53 mutation	Ovarian Cancer	TP53 mutation	Ovarian Cancer	olaparib + capivasertib Sensitive: C3 – Early Trials olaparib + capivasertib Sensitive : C3	olaparib + capivasertib Sensitive: C3 – Early Trials olaparib + capivasertib Sensitive : C3
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	olaparib + capivasertib Sensitive: C3 – Early Trials olaparib + capivasertib Sensitive : C3	olaparib + capivasertib Sensitive: C3 – Early Trials olaparib + capivasertib Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib + capivasertib Sensitive: C3 – Early Trials olaparib + capivasertib Sensitive : C3	olaparib + capivasertib Sensitive: C3 – Early Trials olaparib + capivasertib Sensitive : C3
AKT1 E17K	Breast Cancer	AKT1 E17K	Breast Cancer	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
AKT1 E17K	Estrogen Receptor Positive Breast Cancer	AKT1 E17K	Estrogen Receptor Positive Breast Cancer	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
AKT1 E17K	Solid Tumor	AKT1 E17K	Solid Tumor	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
PTEN deletion + BRCA1 mutation	Breast Cancer	PTEN deletion + BRCA1 mutation	Breast Cancer	olaparib + durvalumab + capivasertib Sensitive: C3 – Early Trials olaparib + durvalumab + capivasertib Sensitive : C3	olaparib + durvalumab + capivasertib Sensitive: C3 – Early Trials olaparib + durvalumab + capivasertib Sensitive : C3
PIK3CA E545K	Breast Cancer	PIK3CA E545K	Breast Cancer	olaparib + durvalumab + capivasertib Sensitive: C3 – Early Trials olaparib + durvalumab + capivasertib Sensitive : C3	olaparib + durvalumab + capivasertib Sensitive: C3 – Early Trials olaparib + durvalumab + capivasertib Sensitive : C3
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	capivasertib + AZD9833 Sensitive: C3 – Early Trials capivasertib + AZD9833 Sensitive : C3	capivasertib + AZD9833 Sensitive: C3 – Early Trials capivasertib + AZD9833 Sensitive : C3
PTEN deletion	Gastric Cancer	PTEN deletion	Gastric Cancer	capivasertib Sensitive: D – Preclinical capivasertib Sensitive : D	capivasertib Sensitive: D – Preclinical capivasertib Sensitive : D
MTOR H1968Y	Melanoma	MTOR H1968Y	Melanoma	capivasertib Sensitive: D – Preclinical capivasertib Sensitive : D	capivasertib Sensitive: D – Preclinical capivasertib Sensitive : D
MTOR S2215Y	Melanoma	MTOR S2215Y	Melanoma	capivasertib Sensitive: D – Preclinical capivasertib Sensitive : D	capivasertib Sensitive: D – Preclinical capivasertib Sensitive : D
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	enzalutamide capsule + capivasertib Sensitive: D – Preclinical enzalutamide capsule + capivasertib Sensitive : D	enzalutamide capsule + capivasertib Sensitive: D – Preclinical enzalutamide capsule + capivasertib Sensitive : D

Truqap (capivasertib)

Associations
(37)

Associations
(37)

Truqap (capivasertib)

Associations(37)

Associations(37)

Associations
(37)

Associations
(37)